AWM
ZVRA icon

Avior Wealth Management’s Zevra Therapeutics ZVRA Stock Holding History

Avior Wealth Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-7
Closed -$40 – 3778
2024
Q1 		$40 Buy
+7
New +$43 ﹤0.01% 3539

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

Avior Wealth Management's ZVRA Position: Q2 2024 in Review

Avior Wealth Management sold out of Zevra Therapeutics (ZVRA) in Q2 2024, closing a stake of 7 shares — an estimated $40 sold.

Avior Wealth Management first reported a position in ZVRA in Q1 2024 and held it in 1 quarter. The position peaked at $40 in Q1 2024. 93 funds tracked by Wall St. Rank hold ZVRA as of Q2 2024.

  • Avior Wealth Management reported no remaining Zevra Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 7 Zevra Therapeutics shares in Q2 2024, an estimated $40.
  • Avior Wealth Management first reported a position in Zevra Therapeutics in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's Zevra Therapeutics position peaked at $40 in Q1 2024.
  • 93 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.